- Home
- FAF vs KNSA Comparison
FAF vs KNSA Comparison
Compare FAF & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FAF | KNSA |
|---|---|---|
| Founded | 1889 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.7B |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | FAF | KNSA |
|---|---|---|
| Price | $67.03 | $95.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $79.00 | ★ $109.43 |
| AVG Volume (30 Days) | ★ 1.1M | 949.6K |
| Earning Date | 10-21-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.61% | N/A |
| EPS Growth | ★ 376.19 | 225.00 |
| EPS | ★ 5.04 | 1.14 |
| Revenue | ★ $7,452,200,000.00 | $677,564,000.00 |
| Revenue This Year | $8.65 | $54.96 |
| Revenue Next Year | $0.61 | $24.16 |
| P/E Ratio | ★ $13.42 | $83.51 |
| Revenue Growth | 21.61 | ★ 60.09 |
| 52 Week Low | $56.20 | $37.02 |
| 52 Week High | $79.87 | $99.31 |
Technical Indicators
Market Signals| Indicator | FAF | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 58.90 |
| Support Level | $63.99 | $72.76 |
| Resistance Level | $67.85 | $98.48 |
| Average True Range (ATR) | 1.96 | 5.47 |
| MACD | 0.46 | 0.57 |
| Stochastic Oscillator | 57.81 | 85.16 |
Price Performance
Historical ComparisonAbout FAF First American Corporation (New)
First American Financial Corp is engaged in the business of providing title insurance, settlement services, and other financial services and risk solutions. The group's reportable segments are: Title insurance and services, Home warranty, and Corporate. Maximum revenue is generated from the Title insurance and services segment, which provides title insurance, closing, escrow, and related services domestically and internationally in connection with residential and commercial real estate transactions. This segment also provides solutions to mitigate risk and facilitate real estate transactions, along with offering banking, trust, warehouse lending, mortgage subservicing and wealth management services. The majority of the group's revenue is generated from escrow fees and insurance premiums.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.